Oncology Central is hosting a free 2-day online educational symposium, chaired by Professor Angus Dalgleish (St George’s, University of London) aimed at delivering oncology professionals key updates in this field. This online symposium will be CME-accredited.
Editor, Jade Parker recently spoke with David Adams, Wellcome Trust Sanger Institute (Cambridge, UK) about utilizing DNA sequencing of patients and genetic screens in human cells and mice to identify cancer genes and genetic interactions.
Editor Jade Parker, speaks to Peter Campbell (Wellcome Trust Sanger Institute, Cambridge, UK) to find out how he is working towards identifying the preventable causes of cancer.
In this interview find out about Anthony Nolan’s research strategy, breakthroughs that have aided the advancement of stem cell transplantation, how third-generation sequencing for HLA typing may improve donor-recipient matching and the direction that Alejandro Madrigal envisions Anthony Nolan’s research will take in the coming years.
Register now for webinar!
Live event: Wednesday 14th June 2017 at 07:00 [PST] 10:00 [EST] 15:00 [GMT]
Learn about a study that was accomplished as a means to explore the hypothesis that circulating concentrations of decoy receptors and/or ligands, as well as disease-specific ligand degradation all regulate RTK signaling in vivo.
Pat Garcia-Gonzalez and Ann Kim Novakowski from The Max Foundation speak to Sebastian Dennis-Beron, commissioning editor at Future Medicine, for Oncology Central.
The expert speakers from our recent webinar on the links between diet and mouth and gastrointestinal cancers address further questions from our audience.
Find out how diet affects the risk of mouth and gastrointestinal cancers, and learn about how people can reduce their risk of developing the disease
Learn how SenoBright can give answers sooner in breast cancer diagnosis, spotlighting areas that may not be visible on a standard mammogram or ultrasound. Listen to the team at Pink Lotus talk about the power of reducing patients’ wait time after an inconclusive mammogram.
Molecular profiling metastatic colorectal cancer (mCRC) patients’ tumors have become a central aspect of a personalized therapy approach to treating mCRC.